See how Coach actually answers

Research suggests 250–500 mcg subcutaneous, administered 2× daily (morning + evening) for 8–12 weeks during active rehab. Inject as proximal to the injury site as practical — site proximity correlates with response time in animal models.

Why oral BPC-157 is a waste: gastric enzymes (pepsin, trypsin, chymotrypsin) destroy the 15-amino-acid chain before systemic absorption. SubQ is the only route with therapeutic plasma concentration data.

Log your first dose to start tracking response.

DISCLAIMER: This is for educational and informational purposes only. DoseCraft does not provide medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare professional before starting, modifying, or stopping any protocol.

Yes — these compounds work on different repair pathways and are genuinely additive, not redundant.

No documented adverse interactions in current literature. Conservative starting protocol: BPC-157 250 mcg 2×/day + TB-500 5 mg every 5 days for 4 weeks, then reassess.

Build this in the Stack Optimizer to see dose-window timing visualized.

DISCLAIMER: This is for educational and informational purposes only. DoseCraft does not provide medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare professional before starting, modifying, or stopping any protocol.

Both are weekly subcutaneous incretin agonists, but they hit different receptors. The difference shows up in efficacy, side-effect profile, and price.

If cost is a factor, semaglutide is generally cheaper. If maximum efficacy with comparable tolerability is the goal, tirzepatide is the better-evidenced choice. Both require slow titration over 16+ weeks to minimize GI effects.

Track your titration schedule in the app — the half-life chart shows when steady-state plasma concentration locks in.

DISCLAIMER: This is for educational and informational purposes only. DoseCraft does not provide medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare professional before starting, modifying, or stopping any protocol.

CJC-1295 No-DAC is a modified Growth Hormone-Releasing Hormone (GHRH) analog. "No-DAC" means it lacks the Drug Affinity Complex modification that extends half-life. Half-life is ~30 minutes, so it produces a sharp GH pulse rather than sustained elevation.

Educational reference only — not medical advice.

Yes for most. Peptides that stimulate receptor pathways desensitize those receptors with continuous use — the response weakens unless you give the system time to reset.

The general rule: if the compound stimulates a receptor that has a known feedback loop (most do), cycle it. If it acts on a structural / repair pathway that doesn't downregulate (BPC-157, some healing peptides), continuous use is defensible.

Set cycle reminders in the app so you don't miss the off-week.

DISCLAIMER: This is for educational and informational purposes only. DoseCraft does not provide medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare professional before starting, modifying, or stopping any protocol.

For most peptides, yes. SubQ delivers slower, more sustained absorption; IM delivers a faster spike. The choice depends on the compound's half-life and the target effect.

Educational reference only — not medical advice.